Zscaler's AI Hype Masks Organic Growth Concerns Despite Strong Financials

What happened

A Seeking Alpha article highlights Zscaler's positioning as a tollbooth for AI agents, emphasizing 26% year-over-year revenue growth in Q2 FY26 to $816 million and annual recurring revenue of $3.4 billion. However, the latest DeepValue master report reveals underlying vulnerabilities, with organic net new ARR excluding the Red Canary acquisition growing only 7% year-over-year to $139 million, indicating slowing momentum. While the company boasts strong free cash flow and a net cash position, GAAP net losses widened to $34.3 million in the latest quarter, and reliance on acquisitions to sustain headline growth raises durability questions. The shift to ARR-focused reporting increases investor scrutiny on whether AI product announcements translate into measurable, recurring commitments rather than mere usage increases. Investors must now weigh the optimistic AI narrative against the need for evidence of organic reacceleration and margin stability in the next 1-2 quarters.

Implication

The AI security narrative is compelling but risks remaining speculative until Zscaler demonstrates tangible net new ARR growth from AI controls, beyond the current 7% ex-Red Canary rate. Strong financials like $3.4 billion ARR and robust free cash flow provide liquidity but do not offset the risk of multiple compression if organic momentum fails to improve. Key near-term catalysts include Q3 FY26 results showing enhanced organic net new ARR and management quantifying AI Security Suite attach rates, which are critical for validating the growth thesis. Without these signals, the stock's elevated valuation—with an EV/EBITDA of 227.6—remains vulnerable to downside if RPO growth or current mix deteriorates from current levels. Therefore, adhering to the DeepValue report's 'WAIT' rating and targeting entry points near $140 offers a more risk-adjusted approach until clarity emerges.

Thesis delta

The new article reinforces Zscaler's AI positioning but does not shift the core investment thesis, which remains focused on organic growth durability. The thesis still hinges on ex-Red Canary net new ARR accelerating within 1-2 quarters and sustained margins, with no new data altering the need for proof before committing capital.